Therion Biologics Corporation
Quick facts
Phase 3 pipeline
- PANVAC™-VF · Oncology
PANVAC-VF is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing ras and CEA tumor-associated antigens.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Therion Biologics Corporation
What is Therion Biologics Corporation's pipeline?
Therion Biologics Corporation has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include PANVAC™-VF.
Related
- Sector hub: All tracked pharma companies